The tomato has been altered to inhibit the enzyme, polygalacturonase, which is involved in breaking down pectin during fruit ripening...Zeneca Plant Science is a subsidiary of U.K.-based Zeneca Group plc. * Zynaxis Inc., of Malvern, Pa., sold rights to its cell tracking reagents to Phanos Technologies Inc., of Beverly Hills, Calif., for $1.1 million plus a multi-year manufacturing agreement and royalties on sales of the research and diagnostic molecules. (c) 1997 American Health Consultants

Unimed made a $500,000 equity investment in Romark and has agreed to buy another $500,000 worth of Romark stock based on achievement of certain milestones...The deal gives Unimed rights to NTZ in the U.S., Canada, Australia and New Zealand. * Calgene Inc., of Davis, Calif., said it developed a transgenic rapeseed plant to boost production of erucic acid, which has industrial applications

Genzyme Transgenics Corp., of Framingham, Mass., reduced its debt by $4 million with the sale of 1.3 million shares of common stock to Genzyme Corp., which now has a 49 percent stake in Genzyme Transgenics. * MicroGeneSys Inc., of Meriden, Conn., said its influenza vaccine is effective at inducing protective immune responses, but with fewer side effects than current vaccines...for Dexanabinol (HU-211), which is being developed for stroke, head injury and cardiac arrest. * StressGen

Ltd., of Shiga, Japan licensed technology from Indiana University School of Medicine to boost transduction efficiency in retroviral gene therapy...The school's researchers, along with scientists from Northwestern University in Evanston, Ill., and Takara developed a method of using fibronectin fragments to help insert genes into stem cells with retroviruses. * Repligen Corp., of Cambridge, Mass., said it collected more than $10.8 million from the fourth and final installment to Repligen Clinical

The funds will be used to support research of Cellex's Oxycell cell culture technology for growth of normal human bone marrow. * BioChem Pharma Inc., of Laval, Quebec, said shareholders approved a rights plan that had been adopted by the board in April...Also, the company's president and CEO, Francesco Bellini, said regulatory filings for the HIV drug 3TC are nearly complete and the drug is expected to be commercially available toward the end of the year. * T Cell Sciences Inc., of Needham, Mass

Cortech Inc., of Denver, adopted a shareholder rights plan to prevent unwanted takeovers...The company said the move was not a response to any specific acquisition proposal...The funds will be used to support research of Cellex's Oxycell cell culture technology for growth of normal human bone marrow. (c) 1997 American Health Consultants

Cortech Inc., of Denver, adopted a shareholder rights plan to prevent unwanted takeovers...The company said the move was not a response to any specific acquisition proposal...The funds will be used to support research of Cellex's Oxycell cell culture technology for growth of normal human bone marrow. (c) 1997 American Health Consultants

patents related to its "universal donor" cell program...5,413,213 covers human epithelial cells carrying a specific genetic modification designed to reduce tissue rejection following transplantation...and Europe covering its Hepatic Avoidance using Lymphatic Output liver bypass oral drug delivery system., which is designed to enhance absorption of poorly bioavailable drugs. (c) 1997 American Health Consultants

The Phase III study is slated to begin this fall...Oconase is an enzyme designed to degrade RNA within cancer cells. * Aprogenex Inc., of Houston, raised $4 million through the sale of convertible preferred stock...The company said it has funds to keep operating through early 1996. * Athena Neurosciences Inc., of South San Francisco, and Eli Lilly and Co., of Indianapolis, amended their agreement on development of treatments for Alzheimer's disease to include joint ownership rights to their

The vaccine is designed to suppress abnormal T cells by boosting the release of regulatory cytokines...The company said that in addition to enhancing regulatory cell responses, patients experienced a decreased immune response to myelin basic protein, which is linked to multiple sclerosis. * Genetic Therapy Inc., of Gaithersburg, Md., began a Phase I/II trial of its gene therapy for treatment of Fanconi anemia, a fatal disorder that prevents the bone marrow from producing white and red blood cells

The company received no proceeds. * Genentech Inc., of South San Francisco, and Roche Holdings Inc., of Basel, Switzerland, are changing the form of their agreement made earlier this month because Genentech's stockholders are not expected to vote on the matter until after June 30...Terms of the deal are unchanged. (See BioWorld Today, May 2, 1995, p. 1.) * IBEX Technologies Inc., of Montreal, began a Phase I trial of its lead compound, Neutralase (heparinase I), which is being developed for the

SangStat Medical Corp., of Menlo Park, Calif., received FDA marketing approval for Cross-Stat, a monitoring device used to identify organ donors...Also, Du Pont agreed not to sell any DNAP stock it holds before March 1996...The antisense oligonucleotide, which has shown activity against tumors in animal models, is expected to be taken into the clinic in 1996. * Alexion Pharmaceuticals Inc., of Cambridge, Mass., unveiled a new class of recombinant autoantigens, called Apogens, for the treatment of

About 6.9 million Ligand shares will be issued in the merger, giving Glycomed shareholders about 25 percent ownership on a fully diluted basis. (See BioWorld Today, Feb. 8, 1995, p 1.) * CytRx Corp., of Atlanta, completed the formation of Proceutics Inc., a wholly owned subsidiary that will offer preclinical development and analysis services to the pharmaceutical and biotechnology industries. * Ciba Seeds, a Greensboro, N.C.-based division of Ciba-Geigy Corp., was granted deregulation by the

In addition, Genta Jago returned to Genta rights to its Anticode products. * Gilead Sciences Inc., of Foster City, Calif., began Phase I/II studies of its antiviral drug, Cidofovir topical gel, for genital herpes simplex virus in patients with normal immune systems...The two companies were developing the drug to prevent cryptosporidiosis in HIV patients and Immucell expects to have Phase I/II trial results by the end of the year

An option to license the technology was part of a 1993 collaboration between the two companies...GenESA is designed to diagnosis coronary artery disease in association with other devices in patients who cannot exercise adequately. * Genta Inc., of San Diego, expanded its joint venture, Genta Jago, with Switzerland-based Jagotec AG to develop controlled-release oral formulations of 35 drugs already on the market

Net proceeds to the company totaled $1.34 million...The company said Neu-Sensamide showed results similar to two other antiemetic agents, metoclopramide and Odansetron...The company said that before proceeding to the second group of 15, the treatment had to demonstrate an anti-tumor response in "one or more" of the 15 patients in the first group

Net proceeds to the company totaled $1.34 million...The company said Neu-Sensamide showed results similar to two other antiemetic agents, metoclopramide and Odansetron...The company said that before proceeding to the second group of 15, the treatment had to demonstrate an anti-tumor response in "one or more" of the 15 patients in the first group

Xoma gets rights to single-chain antigen-binding proteins and related technologies of Enzon and Creative BioMolecules for products targeting T cells...In return, Enzon and Creative BioMolecules were granted rights to Xoma's bacterial secretion technology for production of single-chain antigen-binding protein...and Alpha 1 Biomedicals Inc., reacquired Far Eastern marketing rights to HGP-30, a potential HIV vaccine/treatment. * Genta Inc., of San Diego, completed a previously announced offering of 4.7

Other News To Note Centocor Inc., of Malvern, Pa., said ReoPro, an anti-platelet drug, has been cleared for marketing in Germany and France for high-risk angioplasty patients